>
Axonics Inc logo

AXNX - Axonics Inc Share Price

$52.74 -0.3  -0.6%

Last Trade - 11/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.58bn
Enterprise Value £1.42bn
Revenue £79.0m
Position in Universe 2121st / 6852
Bullish
Bearish
Unlock AXNX Revenue
Momentum
Relative Strength (%)
1m -13.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.13 0.71 13.8 111.5 178.7 245.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AxonicsInc revenues increased 31% to $34.4M. Net loss increased54% to $22.5M. Revenues reflect United States segmentincrease of 29% to $32.3M, International segment increaseof 64% to $2.1M. Higher net loss reflects Sales andmarketing - Balancing value increase of 30% to $19.2M(expense), Research and development - Balancing va increaseof 32% to $8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AXNX Revenue Unlock AXNX Revenue

Net Income

AXNX Net Income Unlock AXNX Revenue

Normalised EPS

AXNX Normalised EPS Unlock AXNX Revenue

PE Ratio Range

AXNX PE Ratio Range Unlock AXNX Revenue

Dividend Yield Range

AXNX Dividend Yield Range Unlock AXNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AXNX EPS Forecasts Unlock AXNX Revenue
Profile Summary

Axonics, Inc., formerly Axonics Modulation Technologies, Inc., is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, and a permanent implant for those patients who experience a successful external trial period. Its product offering also include Bulkamid, which is used to treat patients with stress urinary incontinence.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 2, 2012
Public Since October 31, 2018
No. of Shareholders: 310
No. of Employees: 416
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 41,902,486
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AXNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AXNX
Upcoming Events for AXNX
Thursday 13th May, 2021
Axonics Inc Participate at BofA Securities 2021 Virtual Healthcare Conference
Wednesday 23rd June, 2021
Axonics Inc Annual Shareholders Meeting
Thursday 24th June, 2021 Estimate
Axonics Modulation Technologies Inc Annual Shareholders Meeting
Wednesday 4th August, 2021 Estimate
Q2 2021 Axonics Inc Earnings Release
Tuesday 2nd November, 2021 Estimate
Q3 2021 Axonics Inc Earnings Release
Frequently Asked Questions for Axonics Inc
What is the Axonics Inc share price?

As of 11/05/21, shares in Axonics Inc are trading at $52.74, giving the company a market capitalisation of £1.58bn. This share price information is delayed by 15 minutes.

How has the Axonics Inc share price performed this year?

Shares in Axonics Inc are currently trading at $52.74 and the price has moved by 51.01% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Axonics Inc price has moved by 4.55% over the past year.

What are the analyst and broker recommendations for Axonics Inc?

Of the analysts with advisory recommendations for Axonics Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Axonics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Axonics Inc next release its financial results?

Axonics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Axonics Inc dividend yield?

Axonics Inc does not currently pay a dividend.

Does Axonics Inc pay a dividend?

Axonics Inc does not currently pay a dividend.

When does Axonics Inc next pay dividends?

Axonics Inc does not currently pay a dividend.

How do I buy Axonics Inc shares?

To buy shares in Axonics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Axonics Inc?

Shares in Axonics Inc are currently trading at $52.74, giving the company a market capitalisation of £1.58bn.

Where are Axonics Inc shares listed? Where are Axonics Inc shares listed?

Here are the trading details for Axonics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AXNX
What kind of share is Axonics Inc?

Based on an overall assessment of its quality, value and momentum, Axonics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Axonics Inc share price forecast 2021?

Shares in Axonics Inc are currently priced at $52.74. At that level they are trading at 34.38% discount to the analyst consensus target price of 0.00.

Analysts covering Axonics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.861 for the next financial year.

How can I tell whether the Axonics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Axonics Inc. Over the past six months, the relative strength of its shares against the market has been -2.15%. At the current price of $52.74, shares in Axonics Inc are trading at 6.39% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Axonics Inc PE Ratio?

We were not able to find PE ratio data for Axonics Inc.

Who are the key directors of Axonics Inc?

Axonics Inc's management team is headed by:

Raymond Cohen - CEO
Dan Dearen - PRE
Michael Carrel - CHM
Erik Amble - IND
Robert McNamara - IND
Prabodh Mathur - OTH
Karen Noblett - OTH
Alfred Ford - OTH
John Woock - CMO
Rinda Sama - COO
Nancy Snyderman - IND
Jane Kiernan - IND
David Demski - DRC
Who are the major shareholders of Axonics Inc?

Here are the top five shareholders of Axonics Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 8.35% (3.50m shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 6.01% (2.52m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.03% (2.11m shares)
Andera Partners S.A.S. Private Equity
Percentage owned: 4.74% (1.99m shares)
Longitude Capital Management Co., LLC Venture Capital
Percentage owned: 4.67% (1.96m shares)
Similar to AXNX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.